Evotec Acquires Kinaxo Biotech for up to $22M
February 09, 2011
Evotec Acquires Kinaxo Biotech for up to $22M
The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011 / ProteoMonitor - Analytik Jena Buys Imaging Firm UVP
April 2, 2013 / GenomeWeb Daily News - Evotec Inks Deal with Apeiron to Use Chemical Proteomics in Cancer Drug Development
January 4, 2013 / ProteoMonitor - Evotec Buys Cell-based Reagents Firm for up to $2.9M
January 3, 2013 / GenomeWeb Daily News - DiscoveRx Acquires BioSeek
November 7, 2012 / GenomeWeb Daily News